SCHEMBL4080083

SCHEMBL4080083

N#Cc1ccc(-c2csc(NCCO)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
VCP P55072 1/20 0.59
KDM4E B2RXH2 5/20 0.56
MAOA P21397 9/20 0.53
MAOB P27338 9/20 0.53
KMT2A Q03164 4/20 0.53
MAPT P10636 4/20 0.53
GAA P10253 3/20 0.53
MEN1 O00255 3/20 0.53
HTT P42858 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 2/20 0.51
LMNA P02545 1/20 0.48
MAPK1 P28482 1/20 0.48
CFTR P13569 1/20 0.48
MRE11 P49959 1/20 0.47
ATM Q13315 1/20 0.47
NPC1 O15118 1/20 0.46
STAT1 P42224 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2585048 0.83 GAA (0.52) VCPKDM4EMAOAMAOBKMT2A
SCHEMBL4728318 0.82 VCP (0.49) VCPKDM4EMAOAMAOBKMT2A
SCHEMBL4075234 0.81 MEN1 (0.68) VCPMAOAMAOBKMT2AMAPT
SCHEMBL10352100 0.81 MAPT (0.67) VCPKDM4EKMT2AMAPTGAA
Hydrochloric Acid SCHEMBL10352099 0.80 MAPT (0.65) VCPKDM4EKMT2AMAPTGAA
SCHEMBL2575950 0.80 VCP (0.54) VCPKDM4EMAOAMAOBKMT2A
SCHEMBL28911474 0.78 VCP (0.62) VCPKDM4EMAOAMAOBKMT2A
SCHEMBL2579091 0.78 GAA (0.64) VCPKDM4EMAOAMAOBKMT2A
SCHEMBL3175801 0.77 VCP (0.58) VCPKDM4EMAOAMAOBKMT2A
SCHEMBL10918876 0.77 KDM4E (0.74) VCPKDM4EMAOAMAOBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101501031-B Oxazolidone derivatives as PR modulators WYETH (US) 2012-02-01 CN disclosed
US-7618990-B2 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy WYETH (US) 2009-11-17 US disclosed
CN-101501031-A Oxazolidone derivatives as pr modulators WYETH CORP (US) 2009-08-05 CN disclosed
EP-2054410-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS Wyeth (US) 2009-05-06 EP disclosed
US-20080045556-A1 Oxazolidone derivatives as PR modulators WYETH (US) 2008-02-21 US disclosed
WO-2008021331-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS WYETH (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045556-A1 Oxazolidone derivatives as PR modulators MC2R, NPY1R, PRLHR VCP 2712/4885KDM4E 480/4885MAOA 2026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.